What type of bacterium is Citrobacter koseri (formerly known as Citrobacter diversus)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Characteristics of Citrobacter koseri

  • Citrobacter koseri is a gram-negative bacillus (GNB) 1
  • It is a motile, non-spore-forming facultative anaerobic bacillus belonging to the Enterobacteriaceae family 2
  • C. koseri is a non-sporulating, motile, gram-negative, facultative anaerobic bacteria 3
  • It typically utilizes citrate as the sole carbon source and constitutes part of the normal gastrointestinal flora in humans and animals 2

Pathogenicity and Infections

  • Citrobacter koseri is an opportunistic pathogen that occurs in neonates and immunocompromised patients 1
  • It has been implicated in nosocomial settings leading to infections involving the urinary tract, respiratory tract, liver, biliary tract, meninges, and bloodstream 1
  • C. koseri has been known to cause meningitis and brain abscess in neonates and immunocompromised individuals 4
  • It has also been reported to cause infective endocarditis in immunocompetent adults 5
  • Osteomyelitis secondary to C. koseri is very rare, but has been reported in a healthy young man with no identifiable risk factors 3

Antibiotic Resistance and Treatment

  • Citrobacter koseri is becoming more recognized due to its inherent resistance to ampicillin and emerging drug resistance to beta lactams and aminoglycosides requiring carbapenem therapy 1
  • The American Heart Association (AHA) and Infectious Diseases Society of America (IDSA) recommend the use of combination antibiotic therapy with a beta-lactam and either an aminoglycoside or fluoroquinolones for 6 weeks to treat IE due to non-HACEK GNB 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.